Clover Health Investments is trading lower Tuesday afternoon after the Trump administration proposed flat MA payment rates for 2027.

Clover Health Investments is now a contrarian buy, with the market underestimating its path to profitability in 2026. See why I rate the CLOV stock a Buy.

Over the last six months, Clover Health’s shares have sunk to $2.60, producing a disappointing 13.5% loss - a stark contrast ...

Clover Health Investments Corp (NASDAQ: CLOV) stock is rising Wednesday after the company announced that it expects to achieve its first full-year GAAP net income profitability this year.

What Happened? Shares of health insurance company Clover Health (NASDAQ:CLOV) jumped 2.5% in the afternoon session after ...

Vivek Garipalli, co-founder and Executive Chairman of Clover Health, recently made headlines by purchasing 531,700 shares of Clover Health stock, a transaction worth approximately $1 million. This ...

Clover Health's pivot to profitability over growth following the divestiture of the non-insurance segment at the end of 2023 has led to significant earnings improvements. The newly launched ...

Shares of Clover Health Investments started the Wednesday trading session on a positive note, continuing a solid run since the Franklin-based company announced on June 30 its inclusion in the Russell ...

Shares of Clover Health Investments plummeted more than 20 percent at one point Wednesday afternoon, a day after the Franklin-based health insurance company reported second-quarter results. Online ...